期刊
JOURNAL OF KOREAN MEDICAL SCIENCE
卷 37, 期 14, 页码 -出版社
KOREAN ACAD MEDICAL SCIENCES
DOI: 10.3346/jkms.2022.37.e107
关键词
Vedolizumab; Ustekinumab; Tuberculosis; Inflammatory Bowel Disease
资金
- Korean government (MSIT) [2021R1G1A1094252]
- National Research Foundation of Korea (NRF)
- National Research Foundation of Korea [2021R1G1A1094252] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The study found that the risk of active tuberculosis is low in patients with IBD treated with vedolizumab or ustekinumab in South Korea.
The present study investigated the risk of active tuberculosis in patients with inflammatory bowel disease (IBD) treated with vedolizumab or ustekinumab, in actual clinical settings in a country with an intermediate tuberculosis burden. The medical records of 238 patients with IBD who received vedolizumab or ustekinumab were retrospectively reviewed at a tertiary referral center in South Korea. All patients had >= 3 months of follow-up duration and underwent a latent tuberculosis infection screening test before initiation of the administration of these drugs. Of the 238 patients enrolled, 181 had Crohn's disease, and 57 had ulcerative colitis. During the median 18.7 months of follow-up, active tuberculosis did not develop in any patient treated with vedolizumab or ustekinumab. Therefore, we concluded that the risk of tuberculosis appears to be low in patients with IBD treated with vedolizumab or ustekinumab in South Korea.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据